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In patients presenting with suspected myocardial infarction (MI), beyond the presence or absence of MI, 4 clinical variables seem to affect high-sensitivity cardiac troponin (hs-cTn) concentrations: age, renal dysfunction, time from chest 
pain onset, and sex.1 Among the 4 variables, sex has received the most attention, 
resulting in uncertainty about the need to abandon the 1 overall cutoff in favor of 
sex-specific cutoffs for hs-cTn in the diagnosis of MI.2,3 For high-sensitivity cardiac 
troponin T (hs-cTnT), the only hs-cTn assay approved by the US Food and Drug 
Administration (FDA) until now, this does not seem necessary when applying 99th 
percentiles of healthy individuals, as done outside the United States. With these 
cutoffs, only a very small percentage (<1%) of women were reclassified as having 
MI.2 The FDA-approved use of hs-cTnT differs in using the 99th percentile up-
per reference limit determined in a reference population matched to the age of 
patients presenting with suspected MI to the emergency department. As a conse-
quence, the FDA-approved 1 overall (19 ng/L) and sex-specific (women, 14 ng/L; 
men, 22 ng/L) 99th percentiles are higher compared with the 99th percentiles used 
outside the United States.
The aim of this analysis was to explore the diagnostic reclassifications when us-
ing the FDA-approved sex-specific cutoffs versus the FDA-approved 1 overall cutoff 
for hs-cTnT in a large diagnostic multicenter study enrolling patients presenting 
with suspected MI to the emergency department (NCT00470587). Routine clini-
cal care included medical history, physical examination, 12-lead ECG, continuous 
rhythm monitoring, pulse oximetry, standard blood test, and chest radiography. 
Levels of cardiac troponin were measured with the local cardiac troponin assay (hs-
cTnT in 49.9% of patients) at presentation and serially thereafter as long as clini-
cally indicated. Patients presenting with ST-segment–elevation MI were excluded. 
The final diagnosis was centrally adjudicated by 2 independent cardiologists using 
all available clinical information, including serial measurements of hs-cTnT twice: 
once with the 1 overall cutoff value of 19 ng/L and once with the sex-specific cut-
off values (women, 14 ng/L; men, 22 ng/L). The clinical impact of using sex-specific 
cutoffs was quantified by assessing diagnostic reclassifications when using sex-
specific values. The duration of follow-up was 365 days. The study was approved 
by the local ethics committees, and patients gave informed consent.
Among 4048 patients (1316 women and 2732 men), MI was diagnosed in 634 
patients (15.7%; 168 women [12.8%] and 466 men [17.1%]) with the 1 overall 
cutoff value. Among these, concentrations of hs-cTnT were already greater than or 
equal to the 1 overall cutoff value at emergency department presentation in 551 
patients (sensitivity, 86.9% [95% confidence interval {CI}, 84.0–89.4]; specificity, 
86.7% [95% CI, 85.5–87.8]) with near-identical performance in women (sensitiv-
ity, 87.5% [95% CI, 81.5–91.7]; specificity, 87.7% [95% CI, 85.7–89.6]) and men 
(sensitivity, 86.7% [95% CI, 83.3–89.7]; specificity, 86.1% [95% CI, 84.7–87.5]).
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After readjudication with sex-specific cutoffs, diag-
nostic reclassification occurred in 11 patients: 0.3% 
(95% CI, 0.1–0.5) of all patients and 1.7% (95% CI, 
0.9–3.0) of patients with MI. In 4 women, the diag-
nosis was upgraded from unstable angina to MI, and 
in 7 men, the diagnosis was downgraded from MI to 
unstable angina, overall resulting in 631 patients with a 
final adjudicated diagnosis of MI (versus 634 with the 1 
overall cutoff; Figure). None of the reclassified patients 
died during 365 days of follow-up. Among the 7 down-
graded men, 3 underwent percutaneous coronary in-
tervention and 1 underwent bypass grafting during the 
index admission. Among the 4 upgraded women, 3 un-
derwent percutaneous coronary intervention.
With 14 ng/L used as the 1 overall cutoff value, as done 
outside the United States,2 645 patients (15.9%; 172 
women [13.1%] and 473 men [17.3%]) were diagnosed 
with MI. Again, using the sex-specific cutoffs correspond-
ing to the 1 overall cutoff of 14 ng/L (9 ng/L for women 
and 15.5 ng/L for men) resulted in very few reclassifications 
(2 women were upgraded from unstable angina to MI, 
and 1 man was downgraded from MI to unstable angina).
These findings extend and corroborate recent observa-
tions in 2734 patients using the 99th percentiles of healthy 
individuals in which readjudication with sex-specific 99th 
percentile values resulted in diagnostic reclassification 
for MI in 0.11% (95% CI, 0.02–0.32) of all patients and 
0.6% (95% CI, 0.13–1.85) of patients with MI.2
These findings are explained at least in part by the 
fact that women presenting with suspected MI are on 
average 5 to 8 years older than men presenting with 
suspected MI.1–3 The older age of female patients, 
which is associated with higher hs-cTn concentrations, 
seemed to compensate for the effect of female sex, 
which per se is associated with lower hs-cTn concentra-
tions, obviating the need to adjust cutoffs.
Following the guidelines in place during enrollment, 
overall cutoff values were used for the diagnosis of MI 
and the selection of investigations in the clinical care 
of patients. This should not have introduced a bias 
because hs-cTnT concentrations were comparable in 
women (median, 7.6 [interquartile range, 4.0–16.3] 
ng/L) and men (median, 8.7 [interquartile range, 5.0–
20.0] ng/L; P=0.75).
It is important to highlight that the possible clinical 
use of hs-cTn is currently explored in several additional 
indications beyond the diagnosis of MI and that pros 
and cons of using sex-specific cutoffs may differ in oth-
er emerging indications.4
In conclusion, when the FDA-approved hs-cTnT cut-
off values are used, the 1 overall 99th percentile pro-
vides very high and near-identical sensitivity and speci-
ficity in women and men already at the emergency 
department. Sex-specific cutoff concentrations reclas-
sify a small percentage of patients.
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Figure. Diagnostic reclassifications applying sex-specific cutoffs.  
Flow diagram showing reclassifications among the 5 diagnostic categories when sex-specific cutoffs for high-sensitivity cardiac 
troponin T (women, 14 ng/L; men, 22 ng/L) are used compared with the 1 overall cutoff (19 ng/L). NCCP indicates noncardiac 
chest pain; NSTEMI, non–ST-segment–elevation myocardial infarction; and UA, unstable angina. 
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